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Carbogen and nicotinamidea b s t r a c t
Background and purpose: Addition of carbogen and nicotinamide (hypoxia-modifying agents) to radio-
therapy improves the survival of patients with high risk bladder cancer. The study investigated whether
histopathological tumour features and putative hypoxia markers predicted beneﬁt from hypoxia modiﬁ-
cation.
Materials and methods: Samples were available from 231 patients with high grade and invasive bladder
carcinoma from the BCON phase III trial of radiotherapy (RT) alone or with carbogen and nicotinamide
(RT + CON). Histopathological tumour features examined were: necrosis, growth pattern, growing mar-
gin, and tumour/stroma ratio. Hypoxia markers carbonic anhydrase-IX and glucose transporter-1 were
examined using tissue microarrays.
Results: Necrosis was the only independent prognostic indicator (P = 0.04). Necrosis also predicted ben-
eﬁt from hypoxia modiﬁcation. Five-year overall survival was 48% (RT) versus 39% (RT + CON) (P = 0.32)
in patients without necrosis and 34% (RT) versus 56% (RT + CON) (P = 0.004) in patients with necrosis.
There was a signiﬁcant treatment by necrosis strata interaction (P = 0.001 adjusted). Necrosis was an
independent predictor of beneﬁt from RT + CON versus RT (hazard ratio [HR]: 0.43, 95% CI 0.25–0.73,
P = 0.002). This trend was not observed when there was no necrosis (HR: 1.64, 95% CI 0.95–2.85, P = 0.08).
Conclusions: Necrosis predicts beneﬁt from hypoxia modiﬁcation in patients with high risk bladder can-
cer and should be used to select patients; it is simple to identify and easy to incorporate into routine his-
topathological examination.
 2013 The Authors. Elsevier Ireland Ltd. Radiotherapy and Oncology
108 (2013) 40–47
Open access under CC BY-NC-SA license.
 Muscle invasive bladder cancer has ﬁve-year survival rates of
50–60%. Treatment is with radical cystectomy or bladder-sparing
protocols involving radiotherapy. Both show similar survival rates
[1,2] with the latter preserving a functional bladder in three quar-
ters of patients [3]. The BCON (bladder carbogen and nicotinamide)
phase III clinical trial showed the addition of carbogen and nicotin-
amide (CON) to radiotherapy (RT) improved overall survival (OS)
[4]. Not all patients beneﬁt from the additional hypoxia-modifyingtherapy and there is a need for biomarkers to improve the individ-
ualisation of bladder cancer treatment.
There is evidence in head and neck cancer that hypoxic tumours
beneﬁt most from hypoxia-modifying therapy [5–10]. Similar evi-
dence is not available for bladder cancers but, like other solid tu-
mours, they contain hypoxic areas and the expression of high
levels of hypoxia-inducible markers is associated with a poor prog-
nosis [11–13].
There is no means to routinely measure tumour hypoxia in the
clinic. Once considered the gold standard, the Eppendorf pO2 histo-
graph is no longer available, endogenous protein markers suffer
poor speciﬁcity [14] and large intra-tumour variation [15], and
exogenous nitroimidazole markers require intravenous/oral
administration and the need for prospective assessment has lim-
ited the number of studies carried out [16]. As a simple histopa-
thology approach would be an advantage, we hypothesised that
tumour features such as necrosis, growth pattern, appearance of
Fig. 2. H&E-stained bladder cancer section with necrosis. Necrosis is identiﬁed by
the presence of cell ghosts and is eosinophilic and granular. Original magniﬁcation
400.
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mour hypoxia as well as putative hypoxia markers carbonic anhy-
drase-IX (CA-IX) and glucose transporter-1 (Glut-1).
Tumour necrosis is believed to represent the endpoint of severe,
chronic hypoxia distal to functional blood vessels. In bladder can-
cer, necrosis has been associated with the expression of hypoxia
markers hypoxia inducible factor-1 and CA-IX and a poor outcome
following primary cystectomy [13]. Tumour growth pattern [17]
and appearance of growing margin [18] are also associated with
a poor prognosis in urothelial disease. Solid growing tumours
may be more hypoxic; they comprise large tumour islands, which
may have less well organised vasculature than papillary tumours.
An inﬁltrative tumour margin may indicate the presence of hypox-
ia, which can drive invasion and metastasis [19]. TSR may also be
indicative of tumour hypoxia. Stromal expression of the hypoxia
marker, monocarboxylate transporter 4 predicts poor outcome in
breast cancer [20] and high levels of tumour stroma (>50%) have
been linked to a worse prognosis in several cancer types [21–24].
Expression of CA-IX and Glut-1 was associated with a poor survival
in bladder cancer [11], and so may also predict treatment beneﬁt.
Therefore, a retrospective study was performed to investigate the
ability of the various histopathological features and putative hy-
poxia markers to predict beneﬁt from hypoxia modiﬁcation using
samples from patients enrolled in the BCON trial. REMARKFig. 1. CONSORT diagram.
Table 1
Clinicopathologic patient details grouped by random assignment.
Variable RT RT + CON P
N = 119 N = 112
Gender 0.55
Male 93 (78%) 92 (82%)
Female 26 (22%) 20 (18%)
Age (years) 75 (51–90) 75 (51–89) 0.54
Tumour stage 0.49
T1 12 (10%) 10 (9%)
T2 75 (63%) 80 (71%)
T3 27 (23%) 17 (15%)
T4a 5 (4%) 5 (4%)
TURBT 0.89
Complete 47 (39%) 44 (39%)
Partial 34 (29%) 36 (32%)
Biopsy 32 (27%) 29 (26%)
No data 6 (5%) 3 (3%)
Radiotherapy 0.58
32 fractions 80 (67%) 81 (72%)
20 fractions 38 (32%) 28 (25%)
Other 1 (1%) 3 (3%)
Necrosis 0.83
Present 61 (51%) 60 (54%)
Absent 58 (49%) 52 (46%)
Growth pattern 0.24
Papillary 19 (16%) 26 (23%)
Solid 50 (42%) 49 (44%)
Both 50 (42%) 37 (33%)
Growing margin 0.33
Broad 5 (4%) 2 (2%)
Inﬁltrative 114 (96%) 109 (97%)
Both 0 1 (1%)
TSR 0.33
High P50% 108 (91%) 101 (90%)
Low <50% 9 (7%) 11 (10%)
Mixed 2 (1%) 0 (0%)
Concurrent pTis 0.006
Present 40 (34%) 19 (17%)
Absent 79 (66%) 93 (83%)
Hb (g/dL) 13.6 (9.3–16.9) 14.1 (9.5–17.2) 0.29
No data 1 (1%) 1 (1%)
CA-IX score 4.8 (0–208.4) 4.5 (0–148.9) 0.81
No data 23 (19%) 19 (17%)
Glut-1 score 110.0 (0–300) 90.9 (0–290.0) 0.61
No data 24 (20%) 22 (20%)
Data are represented as n (%) or median (range). Abbreviations: RT, radiotherapy;
CON, carbogen and nicotinamide; TURBT, transurethral resection of the bladder
tumour; CIS, carcinoma in situ; Hb, haemoglobin.
42 Necrosis/beneﬁt from hypoxia modiﬁcationguidelines for reporting prognostic tumour marker studies were
followed throughout [25].Materials and methods
Patients and tissue samples
A retrospective cohort studywas carried out in 231 patientswith
histologically proven high grade urothelial (transitional cell) carci-
noma of the bladder, stage T1, T2, T3 or T4a (metastases free). Pa-
tients participated in the prospective BCON phase III trial and
were randomised betweenNovember 2000 andApril 2006. Samples
from 11 UK hospitals were obtained for 251 of the 333 patients en-
rolled in BCON. Samples from 20 patients were excluded as they
were: low grade [1], squamous cell [2], reclassiﬁed as T4b [2], or
contained insufﬁcient tumour material [15]. Fig. 1 is the CONSORT
diagram. The study was approved by the local research ethics com-
mittee (LREC 09/H1013/24) and informed consent for sample col-
lection and analysis before randomisation was mandatory.Two RT schedules were permitted: 55 Gy in 20 fractions in four
weeks and 64 Gy in 32 fractions in 6½ weeks. Treatments were gi-
ven daily, ﬁve times per week and all ﬁelds were treated in each
session. Carbogen (2% CO2 and 98% O2) was administered 5 min-
utes before and during RT. An oral dose of 40 or 60 mg kg1 nico-
tinamide (Larkhall Laboratories, Charlbury, UK) was given 1½ to
2 h before each fraction.
Tissue samples were obtained by pre-treatment transurethral
resection of the bladder tumour (TURBT; biopsy, partial or com-
plete). Tumour debulking was performed using a diathermy loop,
which produced strips of tissue approximately 6 mm in width
and of variable length. One block per cm tumour diameter was for-
malin-ﬁxed and parafﬁn-embedded (FFPE). Up to eight blocks per
patient were examined to assess intra-tumour heterogeneity.
For independent validation of the prognostic ability of necrosis,
raw data were obtained from a previously published study [13].
Brieﬂy, samples were obtained from 90 patients who underwent
radical cystectomy for invasive and high grade bladder cancer.Histopathology
One 4 lm haematoxylin and eosin (H&E)-stained section from
each FFPE block was analysed. Staging was clinical and pathologi-
cal (TNM AJCC/UICC classiﬁcations). Grading was according to UK
Royal College Pathologists (RCP) guidelines (WHO 1973). Tissue
hypoxia-related coagulative tumour necrosis is characterised by
increased tissue eosinophilia, nuclear breakdown and ultimate loss
of tissue architecture (Fig. 2). Following REMARK guidelines, cut-
off values were selected from the literature prior to scoring. Necro-
sis was scored as absent versus present (any amount) as used in
routine histopathology reporting for other cancers. Growth pattern
was recorded as solid (ﬂat, broad base), papillary (polypoid), or
both; growing margin as broad, inﬁltrative (narrow cords or single
cells at invasive front), or both. For TSR, patients with <50% were
classiﬁed as TSR low and patients with P50% as TSR high. This
cut-off was determined to have maximum discriminative power
in colon [21], oesophageal [22], and breast [23,24] cancer. As it is
a recognised prognostic factor [26], presence of ﬂat carcinoma
in situ (CIS or pTis) was recorded at the same time. Two consultant
histopathologists assessed the slides (HD & SA) as in routine
pathology reporting with no double scoring. In case of tumour het-
erogeneity, those areas with the worst histopathological feature
were deemed decisive.Immunohistochemistry
For tissue microarrays, tumour areas were demarcated by a
histopathologist and 1 mm diameter cores (up to 3 per tumour re-
gion from 2 regions) were taken. Where possible, cores were also
taken from regions of normal urothelium. Up to 120 cores were
placed in a single FFPE block in a standardised pattern (MTA-1,
Beecher Instruments, Silver Spring, MD). Immunohistochemistry
was carried out for CA-IX and Glut-1 as described previously
[11]. In a subset of cases, immunohistochemistry for Ki-67 was also
performed [11].Immunohistochemical analysis
CA-IX and Glut-1 were assessed using an H-score – the product
of intensity (0–3) and estimated percentage labelling of viable tu-
mour cells in cores (100 magniﬁcation), giving a range of 0-300.
Ki-67 was scored on a ﬁeld-by-ﬁeld basis (400 magniﬁcation) as
a percentage of viable tumour cells labelled. Two observers (AE &
JJI) scored cores independently and a mean score was taken.
Independent scores correlated well (Spearman q: CA-IX = 0.90,
Glut-1 = 0.90, Ki-67 = 0.85). Discordant cases were re-scored by a
Table 2
Hazard ratios for all cause mortality in patients treated with RT alone. All covariates included in the model are also tabulated.
Variable NUV HRUV 95% CI P NMV HRMV 95% CI P
Gender 119 0.22 87 0.25
Male (reference) 93 70
Female 26 1.41 0.82–2.42 17 1.57 0.73–3.37
Age (years)* 119 1.05 1.02–1.08 0.003 87 1.05 1.00–1.09 0.04
Stage 119 0.12 87 0.10
T1 (reference) 12 8
T2 75 3.09 0.96–9.94 58 6.49 0.82–51.1
T3 27 2.31 0.66–8.10 18 3.96 0.43–36.5
T4a 5 3.89 0.78–19.34 3 6.75 0.51–88.7
TURBT 113 0.90 87 0.59
Complete (reference) 47 33
Partial 34 0.90 0.49–1.63 29 0.80 0.39–1.65
Biopsy 32 1.04 0.58–1.87 25 0.66 0.30–1.46
Necrosis 119 0.01 87 0.04
Absent (reference) 58 38
Present 61 1.82 1.12–2.96 49 2.11 1.04–4.28
Growth pattern 119 0.44 87 0.47
Papillary (reference) 19 4
Solid 50 1.13 0.58–2.20 42 1.94 0.40–9.37
Both 50 0.80 0.40–1.59 41 1.38 0.27–7.02
pTis 119 0.03 87 0.02
Absent (reference) 79 56
Present 40 1.71 1.05–2.77 31 2.18 1.17–4.06
Hb (g/dL)* 118 0.86 0.73–1.01 0.07 87 0.91 0.73–1.13 0.38
CA-IX score 96 0.10 87 0.78
0 (reference) 31 29
>0 65 1.62 0.90–2.92 58 1.12 0.52–2.41
Glut-1 score 95 0.65 87 0.66
<100 (reference) 44 42
P100 51 1.13 0.66–1.92 45 1.15 0.61–2.18
Abbreviations: HR, hazard ratio; UV, univariate; MV, multivariate; TURBT, transurethral resection of the bladder tumour; pTis, carcinoma in situ; Hb, haemoglobin.
* Variables marked with a * were entered as continuous variables and hence the HR is for a unit increase in the variable.
A. Eustace et al. / Radiotherapy and Oncology 108 (2013) 40–47 43consultant histopathologist (HD) and their score used. Scorers
were blinded to clinical outcome data. Tumour cores were not
scored if there was <10% viable tumour. The mean (range) number
of cores scored were 4.3 (1–6), 4.3 (1–6) and 2.1 (1–3) for CA-IX,
Glut-1 and Ki67, respectively. In normal urothelium, median scores
(CA-IX and Glut-1) were 0 and median% Ki-67 was 0. An a priori
cut-off point of 0 was selected to dichotomise patients as previ-
ously described for CA-IX [11,13] and Glut-1 [11]. However, for
Glut-1, a cut-off of 100 was then selected retrospectively as it
was close to the median value and because only 9 cases (4.9%)
were negative.Statistical analyses
Statistical analyses were performed using S Plus (Insightful Cor-
poration, Seattle, WA). Five-year OS was taken as time from ran-
domisation to death from any cause; patients still alive were
censored at the time last seen or at ﬁve years whichever was ear-
lier. Local relapse free survival was taken as time to tumour recur-
rence in bladder (muscle invasive lesions only), locoregional failure
or death from any cause. Patients alive and free of local disease
were censored at their last follow-up. Patients with persistent
muscle invasive or with no cystoscopy following treatment had
their time set to zero. Fifty-four patients had a follow up beyond
ﬁve years, of which 43 were censored. Follow up beyond ﬁve years
was not routinely reported at all hospital sites. Survival estimates
were obtained using the Kaplan–Meier method and differences
compared using the Mantel-Cox log-rank test. Hazard ratios (HR)
and 95% CI were obtained using Cox’s proportional hazard model.
Heterogeneity in the treatment effect according to necrosis was ad-dressed within a stratiﬁed Cox regression model using appropriate
stratum speciﬁc-treatment variables. This analysis was performed
ﬁrst just with necrosis, CA-IX or Glut-1 and treatment information
and second adjusted for prognostic features. The chi-square test
was used to compare proportions across the levels of categorical
factors and Yates’ correction was used for 2  2 tables; the
Mann-Whitney U test was used to compare median values for con-
tinuous variables between two groups. Spearman correlation coef-
ﬁcients were used to assess statistical associations. All P-values
were two-sided and signiﬁcance was set to P 6 0.05.
Results
In the subset of 231 BCON patients available for study, 119
received RT alone and 112 RT + CON. Most patients (229; 99%)
received P90% of the prescribed RT (i.e. 20 or 32 fractions). In
the experimental arm, 100 patients (89%) received P90% of the
stipulated carbogen doses and 81 (72%) received P90% of the nic-
otinamide at the dose of 60 mg/kg. The 231 patients had a median
age at randomisation of 75 (range 51–90) years. 185 (80%) patients
were male and 46 (20%) female. Stage was T1, T2, T3, T4a in 22
(10%), 155 (67%), 44 (19%) and 10 (4%) patients, respectively.
Table 1 lists clinicopathologic details by randomisation arm. Sup-
plementary Table S1 shows the clinicopathologic details for the
necrosis cohort were very similar to those for patients enrolled
in the main trial.
Tumour necrosis was evident in 121 (52%) patients. Supplemen-
tary Table S2 shows the distribution of patients in the necrotic and
non-necrotic sub-groups by randomisation arm. As most tumours
had an inﬁltrative growing margin and high TSR (Table 1), these
Fig. 3. Kaplan–Meier plots for: (A, C, D) overall survival of BCON patients who received radiotherapy as primary treatment and (B) cancer-speciﬁc survival of patients who
underwent radical cystectomy as primary treatment [13]. Patients are stratiﬁed by the absence or presence of necrosis (A, B), CA-IX score (C) or Glut-1 score (D). Log rank P
values and number of patients at risk in each yearly interval are also shown.
44 Necrosis/beneﬁt from hypoxia modiﬁcationfeatures were not investigated further. Median CA-IX and Glut-1
scores were 4.7 (range 0–208.4; 189 cases) and 103.9 (range
0–300; 185 cases) respectively. Median proliferative fraction as
deﬁned by percentage Ki-67 immunolabelling was 10.4% (range
0–72.8%; 92 cases). There were 63 (33.3%), 9 (4.9%) and 1 (1.1%) tu-
mour(s) that were negative for CA-IX, Glut-1 and Ki-67,
respectively.
Analyses were carried out for OS and local relapse free survival
but as the results were very similar, the ﬁndings for OS only are
presented. Prognosis was investigated in 119 patients receiving
RT alone as this was deﬁned as standard bladder-sparing treat-
ment. Table 2 summarises the results of univariate and multivari-
ate analyses. Increasing age (P = 0.003), presence of necrosis
(P = 0.01), and concurrent pTis (P = 0.03) were the only statistically
signiﬁcant adverse prognostic factors upon univariate analysis. Age
(P = 0.04), necrosis (P = 0.04), and concurrent pTis (P = 0.02) re-
tained signiﬁcance upon multivariate analysis. Fig. 3A shows that
necrosis is a signiﬁcant prognostic factor in high grade and invasive
bladder cancer treated with RT alone (log rank P = 0.01). Five-year
OS was 48% in the absence of necrosis and 34% in the presence of
necrosis. Supplementary Fig. S1 shows the result for local relapse
free survival (log rank P = 0.016). In the same cohort of patients
neither CA-IX (Fig. 3C) nor Glut-1 (Fig. 3D) had prognostic signiﬁ-cance. Given the strong prognostic signiﬁcance of necrosis, an
independent cohort was obtained. The cohort comprised a pub-
lished series of bladder cancer patients undergoing radical cystec-
tomy, which showed that necrosis was prevalent in high grade and
invasive disease (46/91, 51%). The patient and tumour characteris-
tics for the cohort have already been published [13]. Tumour
necrosis scored on whole sections as absent, comedo (<5 mm), or
gross (>5 mm) was prognostic (log rank P < 0.0001) [13]. The raw
data were obtained and necrosis reanalysed as absent versus pres-
ent as used in our study and in standard histopathology reporting.
Fig. 3B shows that necrosis was prognostic for an adverse outcome
in the independent cohort. Cancer-speciﬁc survival was 82% in the
absence and 59% in the presence of necrosis (log rank P = 0.01).
As necrosis was the only histopathological feature with prog-
nostic signiﬁcance, it was the only one studied further for its ability
to predict beneﬁt from hypoxia modiﬁcation. Of the 231 cases, 124
patients died within ﬁve years (54%). Median follow-up of the 107
survivors was 5.0 (range 1.7–5.0) years. Five-year OS was 41% for
RT alone versus 48% for RT + CON (log rank P = 0.14). In 110 pa-
tients with no evident necrosis the ﬁve-year OS was 48% for RT
alone versus 39% for RT + CON (log rank P = 0.32) (Fig. 4A). In 121
patients with tumour necrosis the ﬁve-year OS was 34% for RT
alone versus 56% for RT + CON (log rank P = 0.004) (Fig. 4B).
Fig. 4. Kaplan–Meier plots for: overall survival after radiotherapy (RT) alone or with carbogen and nicotinamide (RT + CON) and stratiﬁed according to the (A) absence or (B)
presence of necrosis, (C) CA-IX score = 0 or (D) >0, or (E) Glut-1 score <100 or (F)P100. Log rank P values and number of patients at risk in each yearly interval are also shown.
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free survival. Beneﬁt from the addition of CON to RT was seen in
patients with tumour necrosis (log rank P = 0.001) but not in those
without (log rank P = 0.24). For comparison and because of theirwide use as hypoxia markers, the ability of CA-IX and Glut-1 to
predict beneﬁt from hypoxia modiﬁcation was also studied. In 63
patients with CA-IX score = 0, there was no signiﬁcant difference
in ﬁve-year OS (41% for RT alone versus 51% RT + CON, log rank
Table 3
Multivariate Cox regression stratiﬁed by necrosis. All covariates included in the model
are also tabulated (note the stratum speciﬁc treatment variables, strata:treatment
interaction P = 0.007 unadjusted, P = 0.001 adjusted).
Variable NMV HRMV 95% CI P
Gender 0.32
Male (reference) 177
Female 43 1.28 0.79–2.05
Age (years)* 220 1.05 1.03–1.08 <0.0001
Stage 0.16
T1 (reference) 20
T2 148 2.16 0.94–5.00
T3 42 1.55 0.60–4.00
T4a 10 2.13 0.64–7.09
TURBT 0.63
Complete (reference) 90
Partial 70 0.99 0.64–1.53
Biopsy 60 1.22 0.78–1.93
pTis 0.05
Absent (reference) 162
Present 58 1.52 1.01–2.29
Hb (g/L)* 220 0.89 0.77–1.00 0.06
Necrosis absent:treatment 0.08
RT (reference) 55
RT + CON 50 1.64 0.95–2.85
Necrosis present:treatment 0.002
RT (reference) 57
RT + CON 58 0.43 0.25–0.73
Abbreviations: HR, hazard ratio; MV, multivariate; TURBT, transurethral resection of
the bladder tumour; pTis, carcinoma in situ; Hb, haemoglobin.
BCON patients with all clinicopathologic variables recorded n = 220; 2 cases Hb and
9 cases TURBT not reported.
* Variables marked with a *were entered as continuous variables and hence the HR
is for a unit increase in the variable.
46 Necrosis/beneﬁt from hypoxia modiﬁcationP = 0.52) (Fig. 4C). In 126 with CA-IX score >0, the ﬁve-year OS was
35% for RT alone versus 51% for RT + CON (log rank P = 0.03)
(Fig. 4D). Stratiﬁcation of 185 patients based upon Glut-1 score re-
vealed no signiﬁcant differences in survival between trial arms
(Fig. 4E and F). Given its potential to affect tumour hypoxia, pa-
tients were also stratiﬁed according to haemoglobin levels (using
previously determined cutoffs [27]); no signiﬁcant differences in
survival between trial arms were observed (Supplementary
Fig. S2).
Multivariate analyses showed that only necrosis was a signiﬁ-
cant independent predictor of beneﬁt from CON. The risk of death
was lower when a patient received RT + CON compared to RT alone
when necrosis was present (HR 0.43, 95% CI 0.25–0.73, P = 0.002).
This trend was not observed when necrosis was absent (HR 1.64,
95% CI 0.95–2.85, P = 0.08) (Table 3). Tests for heterogeneity in
treatment effect by necrosis strata were signiﬁcant (P = 0.007
unadjusted, P = 0.001 adjusted). A test for interaction also showed
there was a signiﬁcant treatment effect by necrosis strata for local
relapse free survival (P = 0.003 unadjusted, P = 0.0003 adjusted).
Supplementary Tables S3 and S4 show the comparative data for
CA-IX (P = 0.08 unadjusted, P = 0.20 adjusted) and Glut-1
(P = 0.75 unadjusted, P = 0.61 adjusted) respectively. Haemoglobin
also showed no signiﬁcant evidence for treatment interaction
(P = 0.29 unadjusted).
Tumour necrosis was signiﬁcantly associated with TURBT (chi-
square P = 0.03), growth pattern (chi-square P = 0.004), and low Hb
concentration (Mann Whitney U P = 0.0006). There was a greater
likelihood of detecting tumour necrosis with increasing extent of
surgical resection. Intra-tumour heterogeneity in necrosis was
low in mixed TURBT samples; the mean probability that two ran-
domly chosen blocks from a tumour both showed necrosis or
otherwise was 0.83 (weighted mean 0.80; 46 cases, 2–8 blocks)
(Supplementary Table S5). Solid tumours were more likely to benecrotic than papillary or mixed. Tumour necrosis was not associ-
ated with tumour stage (chi-square P = 0.14) but was associated
with CA-IX (n = 189; Mann Whitney U P < 0.0001) and Glut-1
(n = 185; Mann Whitney U P = 0.002) expression (Supplementary
Table S4). Ki-67 showed no signiﬁcant association with necrosis
(n = 92, Mann Whitney U, P = 0.68; Supplementary Fig. S3).
Discussion
Necrosis was the only histopathological tumour feature with
independent prognostic ability. This is the ﬁrst conﬁrmation of
the ﬁndings of a study reporting necrosis to be an independent ad-
verse prognostic factor in high grade and invasive bladder cancer
[13]. In support, Zigeuner et al. [28] showed necrosis predicts clin-
ical outcomes in 1425 patients (from 13 worldwide centres) under-
going radical surgery for urothelial cell carcinoma of the upper
urinary tract [28]. Contrary to previous reports, putative hypoxia
markers CA-IX and Glut-1 [11] did not signiﬁcantly indicate a poor
prognosis possibly due to differences in quantiﬁcation technique
and biological variation between samples. The use of TMAs might
have led to sampling error and could be a limitation of our study.
Other independent adverse prognostic factors were older pa-
tient age and concurrent pTis. Difﬁculties in staging in the absence
of cystectomy may explain why tumour stage was not a prognostic
risk factor. Established prognostic risk factors for bladder cancer
are tumour grade, stage and the presence of concurrent CIS [26].
As a result of heterogeneity in bladder cancer behaviour, these fac-
tors are insufﬁcient to identify patients with a high risk of death
following radical cystectomy or RT. We propose that necrosis is
used for individualised patient prognostication and clinical deci-
sion making. It is simple to measure and could easily be incorpo-
rated into routine histopathological examination. In our
multivariate analysis, classiﬁcation as absent or present (HR 2.1,
P = 0.04) compared favourably with classiﬁcation as presence and
amount (HR 1.9, P = 0.04) as reported by Ord et al. [13].
Necrosis was signiﬁcantly associated with increasing extent of
TURBT, a solid growth pattern and low Hb levels. Association of
necrosis with low Hb supports its link to chronic hypoxia, as low
Hb levels reduce blood oxygen-carrying capacity. Low Hb has also
been associated with a poor response to radiation [27]. The lack of
association between necrosis and tumour stage (as previously re-
ported [13]) may be due to difﬁculties in staging from TURBT.
Association of necrosis with extent of TURBT might relate to an im-
proved chance of detection in larger tissue samples. Patients not
undergoing complete tumour debulking or cystectomy might have
a small risk of misclassiﬁcation due to smaller sample size. TURBT
might be related to tumour volume and so a confounding factor.
Unfortunately tumour volume data were not collected in the BCON
trial so we cannot rule out this possibility.
Necrotic tumours had higher expression of CA-IX and Glut-1,
consistent with it demarcating areas of chronic hypoxia. Expres-
sion of CA-IX or Glut-1 is associated with a poor prognosis follow-
ing RT in head and neck cancer [29,30]. We theorised that necrotic
tumours would have a high proliferation with rapid cell turnover
leading to outstripping of their oxygen supply. The lack of in-
creased Ki-67 expression in necrotic tumours suggests hypoxia
may develop as a result of poor distribution or perfusion of vascu-
lature rather than high cell proliferation. Despite the strong associ-
ation of CA-IX with tumour necrosis many CA-IX positive tumours
(40/84, 47.6%) had no evident necrosis. In these tumours, CA-IX
may be under the control of hypoxia-independent factors. Sam-
pling bias may explain the lack of CA-IX labelling in the presence
of necrosis (19/105, 18.1%). This trend was less clear for Glut-1,
as this marker was less speciﬁc.
Clinical trials using hypoxia-modifying therapies have been
ongoing since the late 1960s. Meta-analysis of all randomised
A. Eustace et al. / Radiotherapy and Oncology 108 (2013) 40–47 47clinical trials of hypoxia-modiﬁcation involving RT showed signif-
icant improvement in local control [31]. However, it is difﬁcult to
evaluate the full beneﬁt of treatment in unstratiﬁed study popula-
tions. We have shown for the ﬁrst time that tumour necrosis inde-
pendently predicts beneﬁt from hypoxia-modifying therapy.
Although CA-IX and Glut-1 have been associated with a poor prog-
nosis in bladder cancer patients [11], only CA-IX predicted treat-
ment beneﬁt; which was subsequently lost upon multivariate
analysis. It is probable that despite being strongly linked to necro-
sis, they lack hypoxia-speciﬁcity, technical and quantitative preci-
sion. Therefore, a prospective trial should be considered using
necrosis to select patients for RT plus hypoxia-modifying therapy
versus a novel intervention in those with no tumour necrosis.
BCON is currently in phase IV evaluation in UK; it is routine treat-
ment for invasive and high grade bladder cancer in Mount Vernon
Hospital, Middlesex, UK and at least two other UK hospitals. This is
an efﬁcacious treatment and the use of necrosis as a companion
biomarker strengthens the case for its widespread uptake. Use of
necrosis to select patients for BCON can improve ﬁve-year OS by
22%.
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